Log in with your email address username.

×

Important notice

doctorportal Learning is on the move as we will be launching a new website very shortly. If you would like to sign up to dp Learning now to register for CPD learning or to use our CPD tracker, please email support@doctorportal.com.au so we can assist you. If you are already signed up to doctorportal Learning, your login will work in the new site so you can continue to enrol for learning, complete an online module, or access your CPD tracker report.

To access and/or sign up for other resources such as Jobs Board, Bookshop or InSight+, please go to www.mja.com.au, or click the relevant menu item and you will be redirected.

All other doctorportal services, such as Find A Doctor, are no longer available.

[Comment] Isavuconazole: a role for the newest broad-spectrum triazole

Invasive mould infection is a serious complication of treatment for acute leukaemia and transplantation and is increasingly identified with other underlying disorders.1,2 In The Lancet, Johan Maertens and colleagues3 report a randomised, double-blind, non-inferiority study comparing a new broad-spectrum triazole, isavuconazole, with the current standard treatment, voriconazole, in 516 adult patients with suspected invasive mould infection. Isavuconazole was non-inferior to voriconazole by the primary endpoint of all-cause mortality at day 42 (19% [48 patients] in the isavuconazole group vs 20% [52 patients] in the voriconazole group) in an intention-to-treat population.

email